News Daiichi teams up with GAIA for cholesterol DTx in Europe Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.
News Orexo exits depression DTx alliance with GAIA Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.
News Orexo buys US rights to GAIA's deprexis digital therapeutic Sweden's Orexo has announced it has bought the exclusive US rights to GAIA’s deprexis, a digital therapy to help patients manage their symptoms of depression and one of the most researched
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.